©The Author(s) 2024.
World J Gastroenterol. Jan 14, 2024; 30(2): 158-169
Published online Jan 14, 2024. doi: 10.3748/wjg.v30.i2.158
Published online Jan 14, 2024. doi: 10.3748/wjg.v30.i2.158
Table 2 Patients with KRAS, NRAS, BRAF mutations according to tumor budding
| Characteristics | Total, n = 112 | Bd 1, n = 87 | Bd 2-3, n = 25 | P value |
| KRAS | 0.064 | |||
| Wild | 53 (47.3) | 45 (51.7) | 8 (32.0) | |
| Mutant | 59 (52.7) | 42 (48.3) | 17 (68.0) | |
| NRAS | 0.275 | |||
| Wild | 107 (95.5) | 82 (94.3) | 25 (100.0) | |
| Mutant | 5 (4.5) | 5 (5.7) | 0 (0.0) | |
| BRAF | 0.597 | |||
| Wild | 106 (94.6) | 82 (94.3) | 24 (96.0) | |
| Mutant | 6 (5.4) | 5 (5.7) | 1 (4.0) |
- Citation: Luo YH, Yan ZC, Liu JY, Li XY, Yang M, Fan J, Huang B, Ma CG, Chang XN, Nie X. Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer. World J Gastroenterol 2024; 30(2): 158-169
- URL: https://www.wjgnet.com/1007-9327/full/v30/i2/158.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i2.158